Johnson & Johnson Unit Agrees to $85 Million Fine for Misbranding Drug

Johnson & Johnson's Scios unit agreed to pay an $85 million fine and plead guilty to misbranding the heart drug Natrecor, the U.S. said. Scios was charged in July with misbranding the medicine because its labeling lacked adequate directions for use. Under a plea agreement reached after months of negotiation with prosecutors, Scios will be placed under organizational probation for three years in addition to paying the fine, Assistant U.S. Attorney Jonathan Schmidt said in a filing today in federal court in San Francisco. A hearing is scheduled for Sept. 28.

Back to news